A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

To join this study, you would need to have a specific type of bladder cancer called intermediate-risk non-muscle invasive bladder cancer (NMIBC). This means the cancer is only on the lining of your bladder and has certain features that put it at a moderate risk of coming back. You must have had surgery to remove all visible cancer within 90 days before joining the study, and your body's organs need to be working well.

You would not be able to join if your bladder cancer has grown into the muscle, has spread to other parts of your body, or is considered either very high risk or very low risk. Also, if you've had cancer in your prostate tube, or in the upper parts of your urinary system recently, or have received similar gene therapy treatments before, you wouldn't be able to take part.

If you decide to join this study, you would first have a surgical procedure called TURBT to remove your bladder cancer. Then, you would be randomly assigned to one of two groups, like flipping a coin. One group will receive the study treatment, cretostimogene grenadenorepvec, given directly into your bladder. This will start with an initial course, followed by maintenance treatments every three months for over a year, as long as your cancer hasn't returned. The other group will be closely monitored directly after your TURBT.

Regardless of your group, your医生 will regularly check for any cancer recurrence. This will involve checking your urine, looking inside your bladder with a camera (cystoscopy), and sometimes taking biopsies. These checks will happen every three months for the first two years, then every six months for another year. You'll also have scans, like a CT or MRI, every 12 months. If you are in the monitoring group and your cancer does return, you might then be offered the cretostimogene treatment. The total duration of active follow-up for the study could be several years.